AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12365087 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial monotherapy maintained alone or in combination
Number of subjects: 48
Study 9677171 — intervention group
Group type: EXPERIMENTAL
Intervention: STD treatment (directly observed, single oral dose)
Number of subjects: 11618
Study 9677171 — intervention group
Group type: COMPARATOR
Intervention: Control arm received anthelminthic and iron-folate (directly observed, single oral dose)
Number of subjects: 11618
Study 7983527 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin (HI)
Number of subjects: 30
Study 7983527 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine insulin (PI)
Number of subjects: 30
Study 7983527 — intervention group
Group type: COMPARATOR
Intervention: Hypoglycemia (20 min and 50 min)
Number of subjects: 30
Study 3142412 — intervention group
Group type: EXPERIMENTAL
Intervention: Copal UA-251 (Philips) self-blood pressure measurement device
Number of subjects: 38
Study 4884653 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 0
Study 4884653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31870314 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise intervention (twice a week for 16 weeks, 45-60 minutes each session)
Number of subjects: 1120
Study 31870314 — intervention group
Group type: COMPARATOR
Intervention: Waiting time control group
Number of subjects: 1120
Study 28063216 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy-dense (LED) snack food
Number of subjects: 77
Study 28063216 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy-dense (HED) snack food
Number of subjects: 77
Study 28063216 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary restraint individuals randomized to LED food
Number of subjects: 77
Study 28063216 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline eating-related variables
Number of subjects: 77
Study 25526228 — intervention group
Group type: COMPARATOR
Intervention: KB220Z
Number of subjects: 10
Study 25526228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 23026057 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (6 mg)
Number of subjects: 20
Study 23026057 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 20
Study 21789658 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch colposuspension
Number of subjects: 450
Study 21789658 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascial retropubic sling
Number of subjects: 450
Study 21789658 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐administered questionnaires
Number of subjects: 450
Study 19690548 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg m(‐2) over 30 min on days 1, 8, and 15, every 4 weeks for 3 cycles)
Number of subjects: 118
Study 19690548 — intervention group
Group type: COMPARATOR
Intervention: Surgery-only
Number of subjects: 118
Study 16803844 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 alone (2 weeks of treatment and 1 week of rest for 6 months, followed by 2 weeks of treatment and 2 weeks of rest for 6 months)
Number of subjects: 280
Study 16803844 — intervention group
Group type: COMPARATOR
Intervention: S-1 plus PSK (the same regimen of S-1 plus daily PSK for 12 months)
Number of subjects: 280
Study 12717216 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus plus steroids (SRL+ST)
Number of subjects: 430
Study 12717216 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus with cyclosporine A plus steroids (SRL+CsA+ST)
Number of subjects: 430
Study 15040375 — intervention group
Group type: EXPERIMENTAL
Intervention: Emerging areas of consensus in consent rules for paediatric research
Number of subjects: 0
Study 15040375 — intervention group
Group type: EXPERIMENTAL
Intervention: UK, European, and International norms on consent rules
Number of subjects: 0
Study 9283538 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious sedation with combined intravenous midazolam, morphine, and promethazine, plus deep sedation with etomidate
Number of subjects: 162
Study 9283538 — intervention group
Group type: COMPARATOR
Intervention: Propofol anesthesia administered by an attending anesthesiologist
Number of subjects: 162
Study 8517422 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprocedural variables
Number of subjects: 1442
Study 8517422 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprocedural variable
Number of subjects: 1442
Study 8517422 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprocedural multivariate model
Number of subjects: 1442
Study 3469057 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 40 mg/day
Number of subjects: 39
Study 3469057 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg/day
Number of subjects: 39
Study 3469057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 28982517 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative biochemical markers (albumin, CRP, hemoglobin, eGFR)
Number of subjects: 2093
Study 28982517 — intervention group
Group type: EXPERIMENTAL
Intervention: Categorized parameters of preoperative biochemical markers
Number of subjects: 2093
Study 28982517 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC curve analysis for albumin
Number of subjects: 2093
Study 28982517 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive values of preoperative biochemical markers
Number of subjects: 2093
Study 27131407 — intervention group
Group type: EXPERIMENTAL
Intervention: Amaranth extract (2 g as single dose)
Number of subjects: 16
Study 27131407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 24884722 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to the 'Living well with asthma' website for 12 weeks
Number of subjects: 0
Study 24884722 — intervention group
Group type: COMPARATOR
Intervention: Usual asthma care for 12 weeks
Number of subjects: 0
Study 21142821 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets with resinate (dextromethorphan loaded into Amberlite IRP-69 resin)
Number of subjects: 0
Study 21142821 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets with physical mixture (dextromethorphan physically mixed with resin)
Number of subjects: 0
Study 21142821 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets with resinate
Number of subjects: 0
Study 21142821 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets with physical mixture
Number of subjects: 0
Study 21142821 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tablets (resinate and physical mixture)
Number of subjects: 0
Study 20337831 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy treatment
Number of subjects: 90
Study 18545786 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine clonixinate (LC)
Number of subjects: 30
Study 18545786 — intervention group
Group type: COMPARATOR
Intervention: Dipyrone (metamizole)
Number of subjects: 30
Study 15933977 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normovolaemic haemodilution (ANH)
Number of subjects: 36
Study 15933977 — intervention group
Group type: COMPARATOR
Intervention: Cell salvage alone
Number of subjects: 36
Study 12856119 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous teicoplanin (6 mg/kg per 12 h for 48 h, then 6 mg/kg daily)
Number of subjects: 12
Study 12856119 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous teicoplanin (30-min administration)
Number of subjects: 12
Study 12856119 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous teicoplanin
Number of subjects: 12
Study 12856119 — intervention group
Group type: COMPARATOR
Intervention: Intravenous teicoplanin
Number of subjects: 12
Study 10582392 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinoprostone
Number of subjects: 156
Study 10582392 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 156
Study 8600201 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.375 mg
Number of subjects: 18
Study 8600201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 1780722 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallium arsenide laser treatment with standard conservative treatment
Number of subjects: 42
Study 1780722 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser treatment with standard conservative treatment
Number of subjects: 42
Study 6153057 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer feedback
Number of subjects: 4
Study 6153057 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician education program
Number of subjects: 4
Study 6153057 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 4
Study 6153057 — intervention group
Group type: COMPARATOR
Intervention: All patient groups (including control)
Number of subjects: 4
Study 28776304 — intervention group
Group type: EXPERIMENTAL
Intervention: Education about oral mucositis prevention, including training and Patient Education Booklet
Number of subjects: 60
Study 28776304 — intervention group
Group type: EXPERIMENTAL
Intervention: Education about oral mucositis prevention
Number of subjects: 60
Study 28776304 — intervention group
Group type: COMPARATOR
Intervention: Control group (no education)
Number of subjects: 60
Study 28027413 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega 3 (1 gm three times daily for 3 months)
Number of subjects: 10
Study 28027413 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (1.5 ml) and hyaluronidase (1500 IU) mixed with lignocaine (biweekly for 6 weeks) and placebo (for 3 months)
Number of subjects: 10
Study 26482279 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib plus everolimus (18 mg/day and 5 mg/day)
Number of subjects: 153
Study 26482279 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent lenvatinib (24 mg/day)
Number of subjects: 153
Study 26482279 — intervention group
Group type: COMPARATOR
Intervention: Single-agent everolimus (10 mg/day)
Number of subjects: 153
Study 23798465 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTT1 null genotype
Number of subjects: 609
Study 23798465 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-GSTT1 null genotype)
Number of subjects: 609
Study 22827783 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazole (MMI) treatment
Number of subjects: 239
Study 22827783 — intervention group
Group type: COMPARATOR
Intervention: Radioiodine (RAI) treatment with thyroxine
Number of subjects: 239
Study 18534441 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated femoral stems
Number of subjects: 61
Study 18534441 — intervention group
Group type: COMPARATOR
Intervention: Non-hydroxyapatite-coated femoral stems
Number of subjects: 61
Study 17700991 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazosentan 0.2 mg/kg/h
Number of subjects: 34
Study 17700991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 17700991 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazosentan (Part B)
Number of subjects: 34
Study 15321807 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum low-fat, high-carbohydrate diet
Number of subjects: 11
Study 15321807 — intervention group
Group type: COMPARATOR
Intervention: High-monounsaturated fat diet
Number of subjects: 11
Study 15588309 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults with PDS
Number of subjects: 10
Study 15588309 — intervention group
Group type: COMPARATOR
Intervention: Non-stutterers (controls)
Number of subjects: 10
Study 10599904 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg doxycycline daily for 14 days
Number of subjects: 20
Study 10599904 — intervention group
Group type: COMPARATOR
Intervention: Control group (no doxycycline)
Number of subjects: 20
Study 8530236 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissecting the ureter at the initiation of laparoscopic hysterectomy
Number of subjects: 60
Study 8530236 — intervention group
Group type: COMPARATOR
Intervention: Control group (not dissecting the ureter)
Number of subjects: 60
Study 1785703 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 120
Study 1785703 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine
Number of subjects: 120
Study 1785703 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 micrograms enprostil
Number of subjects: 120
Study 1785703 — intervention group
Group type: COMPARATOR
Intervention: 30 ml of 0.5 M sodium citrate
Number of subjects: 120
Study 7225999 — intervention group
Group type: EXPERIMENTAL
Intervention: ACM (Adriamycin, Cyclophosphamide, Methotrexate)
Number of subjects: 232
Study 7225999 — intervention group
Group type: EXPERIMENTAL
Intervention: ACM-ADV (alternating ACM and ADV)
Number of subjects: 232
Study 7225999 — intervention group
Group type: EXPERIMENTAL
Intervention: ADV (Actinomycin-D, DTIC, Vincristine)
Number of subjects: 232
Study 29226778 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue: Take Control (FTC)
Number of subjects: 204
Study 29226778 — intervention group
Group type: COMPARATOR
Intervention: MS: Take Control (MSTC)
Number of subjects: 204
Study 29653858 — intervention group
Group type: EXPERIMENTAL
Intervention: rhNGF 10 μg/ml
Number of subjects: 156
Study 29653858 — intervention group
Group type: EXPERIMENTAL
Intervention: rhNGF 20 μg/ml
Number of subjects: 156
Study 29653858 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 156
Study 26817717 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 μg FA/d
Number of subjects: 126
Study 26817717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 25175029 — intervention group
Group type: EXPERIMENTAL
Intervention: Tachosil® application
Number of subjects: 140
Study 25175029 — intervention group
Group type: COMPARATOR
Intervention: No application (Control)
Number of subjects: 140
Study 21812797 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 360mg
Number of subjects: 254
Study 21812797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study 20817653 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise programme at the spine clinic
Number of subjects: 246
Study 20817653 — intervention group
Group type: COMPARATOR
Intervention: Brief intervention programme (control)
Number of subjects: 246
Study 17640853 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34+ selected PBPC (arm A)
Number of subjects: 111
Study 17640853 — intervention group
Group type: COMPARATOR
Intervention: Unselected PBPC (arm B)
Number of subjects: 111
Study 16337574 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐mm ancillary trocars
Number of subjects: 102
Study 16337574 — intervention group
Group type: COMPARATOR
Intervention: 5‐mm ancillary trocars
Number of subjects: 102
Study 12032038 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (EM; 17 mL of 2% lidocaine plus 2 mg of morphine)
Number of subjects: 45
Study 12032038 — intervention group
Group type: EXPERIMENTAL
Intervention: IV morphine (IVM; 17 mL of 2% lidocaine plus 0.2 mL of normal saline, followed by IVM 2 mg IV)
Number of subjects: 45
Study 12032038 — intervention group
Group type: COMPARATOR
Intervention: Control (17 mL of 2% lidocaine plus 0.2 mL of normal saline, followed by 0.2 mL of normal saline IV)
Number of subjects: 45
Study 9536191 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support boosting intervention
Number of subjects: 70
Study 9536191 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study 31739848 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology assisted sleep extension intervention (wearable sleep tracker, smartphone application, weekly didactic lessons, brief telephone coaching)
Number of subjects: 16
Study 31739848 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology assisted sleep extension intervention
Number of subjects: 16
Study 31739848 — intervention group
Group type: COMPARATOR
Intervention: Self-management control group
Number of subjects: 16
Study 29851204 — intervention group
Group type: EXPERIMENTAL
Intervention: Vesatolimod (1-, 2-, or 4-mg) once weekly for 12 weeks
Number of subjects: 192
Study 29851204 — intervention group
Group type: COMPARATOR
Intervention: Placebo once weekly for 12 weeks
Number of subjects: 192
Study 29851204 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (300-mg daily) for 48 weeks
Number of subjects: 192
Study 29231362 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy group (scraping therapy + xuanfei zhisou decoction)
Number of subjects: 80
Study 29231362 — intervention group
Group type: COMPARATOR
Intervention: Chinese herbal medicine group (xuanfei zhisou decoction)
Number of subjects: 80
Study 25042213 — intervention group
Group type: EXPERIMENTAL
Intervention: QUIT intervention of brief clinician advice and up to two drug-use health telephone sessions
Number of subjects: 334
Study 25042213 — intervention group
Group type: COMPARATOR
Intervention: Usual care and information on cancer screening
Number of subjects: 334
Study 23216897 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-month Physical Activity (PA) intervention, involving supervised PA sessions and a behavioural change component.
Number of subjects: 0
Study 23216897 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 0
Study 23216897 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-month Physical Activity (PA) intervention
Number of subjects: 0
Study 19161564 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan
Number of subjects: 0
Study 19161564 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 17597256 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine (0.1 mg/kg, maximum 5 mg)
Number of subjects: 90
Study 17597256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 15585800 — intervention group
Group type: EXPERIMENTAL
Intervention: 1600 IU vitamin D2 and 400 IU vitamin D3
Number of subjects: 18
Study 15585800 — intervention group
Group type: EXPERIMENTAL
Intervention: 3600 IU vitamin D2 and 400 IU vitamin D3
Number of subjects: 18
Study 15585800 — intervention group
Group type: COMPARATOR
Intervention: 400 IU/d vitamin D (control)
Number of subjects: 18
Study 15585800 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU/d vitamin D
Number of subjects: 18
Study 15585800 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 IU/d vitamin D
Number of subjects: 18
Study 11720695 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline or Paroxetine (12 weeks treatment)
Number of subjects: 76
Study 11720695 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 16)
Number of subjects: 76
Study 11720695 — intervention group
Group type: COMPARATOR
Intervention: Nonremitters (n = 16)
Number of subjects: 76
Study 9497787 — intervention group
Group type: EXPERIMENTAL
Intervention: NG-monomethyl-L-arginine, 1-4 mumol/min
Number of subjects: 40
Study 9497787 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline, 60-240 pmol/min
Number of subjects: 40
Study 7930694 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine therapy
Number of subjects: 64
Study 7930694 — intervention group
Group type: COMPARATOR
Intervention: Control (not treated)
Number of subjects: 64
Study 3074298 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0
Study 3074298 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0
Study 3074298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31347768 — intervention group
Group type: EXPERIMENTAL
Intervention: Tris/Arg cleanser
Number of subjects: 34
Study 31347768 — intervention group
Group type: COMPARATOR
Intervention: AEC/AC-based cleanser
Number of subjects: 34
Study 29863451 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 0
Study 29863451 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen plus ovarian suppression
Number of subjects: 0
Study 29863451 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane plus ovarian suppression
Number of subjects: 0
Study 28249592 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling for Depression (CfD)
Number of subjects: 500
Study 28249592 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 500
Study 28249592 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness determined by a patient service receipt questionnaire
Number of subjects: 500
Study 28249592 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcome measures
Number of subjects: 500
Study 23553185 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored intervention combining individual sessions based on motivational interviewing and group sessions
Number of subjects: 365
Study 23553185 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 365
Study 23782520 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized homeopathic treatment
Number of subjects: 189
Study 23782520 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 189
Study 23782520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study 20082131 — intervention group
Group type: EXPERIMENTAL
Intervention: MinVP
Number of subjects: 110
Study 20082131 — intervention group
Group type: EXPERIMENTAL
Intervention: MinVP with AF algorithms
Number of subjects: 110
Study 20082131 — intervention group
Group type: COMPARATOR
Intervention: DDDR (control)
Number of subjects: 110
Study 20082131 — intervention group
Group type: COMPARATOR
Intervention: Control phase (DDDR)
Number of subjects: 110
Study 21444270 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine cavity disinfectants
Number of subjects: 0
Study 21444270 — intervention group
Group type: COMPARATOR
Intervention: Mouthrinse and antiseptic (as chlorhexidine agents)
Number of subjects: 0
Study 21444270 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 15722805 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 17
Study 15722805 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 17
Study 15722805 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 17
Study 15722805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17